Hydroxypropyl-beta-cyclodextrin hybrid nanogels as nano-drug delivery carriers to enhance the solubility of dexibuprofen: Characterization, in vitro release, and acute oral toxicity studies

The purpose of this study was to develop and characterize hydroxypropyl-beta-cyclodextrin (HP beta CD) hybrid nanogels for solubility enhancement of lipophilic drug, dexibuprofen. HP beta CD hybrid nanogels were designed by chemical cross-linking of hydroxypropyl-beta-cyclodextrin with 2-acrylamido-2-methyl propane sulfonic acid (AMPS) via free radical polymerization. Loading efficiency, solubilization, zetasizer, FESEM Fourier transform infrared (FTIR), differential scanning calorimetry (DSC), thermal gravimetric analysis (TGA), powder X-ray diffraction (PXRD), and in vitro drug release analysis were performed for characterization of hybrid nanogels. Efficient solubilization of dexibuprofen has been observed by HP beta CD hybrid nanogels. FTIR, TGA, and DSC studies confirmed the formation of new hybrid nanogels and complexation of dexibuprofen with nanogels. XRD analysis revealed loss of dexibuprofen crystallinity in hybrid nanogels. Highly porous and amorphous nanogels showed a significant dexibuprofen release in aqueous medium. In toxicity studies, no significant changes in behavioral, physiological, biochemical, or histopathological parameters of animals endorsed that developed formulations are non-toxic and biocompatible.